The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.
 
Rona Yaeger
Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines
Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Nataliya Uboha
Stock and Other Ownership Interests - Exact Sciences (I); Natera (I)
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; BeiGene; Bristol Myers Squibb Foundation; Bristol-Myers Squibb/Roche; Eisai; Eisai/MSD; Elevation Oncology; GRAIL; ipsen; Ipsen; Lilly; Merck; Strata Oncology
Research Funding - Arcus Biosciences (Inst); EMD Serono (Inst); ipsen (Inst)
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; I-Mab; Merck; Novartis; SERVIER; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation; Hope for Stomach Cancer
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Joshua Sabari
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech/Roche; Janssen; Janssen (Inst); Loxo/Lilly; Loxo/Lilly (Inst); Medscape; Mirati Therapeutics; Mirati Therapeutics (Inst); Pfizer; Regeneron; Regeneron (Inst); Sanofi; Takeda
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Joel Saltzman
Stock and Other Ownership Interests - GoodRx; Lilly; Sana Biotechnology
 
Julio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; zogen
Consulting or Advisory Role - Exigent Research Network
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Immutep (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); QSAM (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)
 
Andrew Paulson
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Agenus; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - Ideo Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); bristol myers squibb (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Regenxbio (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer
 
Pasi Jänne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Blueprint Medicines; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Puma Biotechnology (Inst); Revolution Medicines (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
Expert Testimony - AstraZeneca
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Marcia Cruz-Correa
Employment - Pan American Center for Oncology Trials
Stock and Other Ownership Interests - Pan American Center for Oncology Trials
Research Funding - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GENFIT (Inst); HUYA Bioscience International (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); VMO (Inst)
Patents, Royalties, Other Intellectual Property - Licencing agreement with Johns Hopkins University on technology.
 
Amy Min Kyung Kim
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Nan Hu
No Relationships to Disclose
 
Harris Ahmad
Other Relationship - Bristol-Myers Squibb
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis